Journal Mobile Options
Table of Contents
Vol. 17, No. 3, 2004
Issue release date: March 2004
Dement Geriatr Cogn Disord 2004;17:196–203

Incidence and Risk Factors for Mild Cognitive Impairment: A Population-Based Three-Year Follow-Up Study of Cognitively Healthy Elderly Subjects

Tervo S. · Kivipelto M. · Hänninen T. · Vanhanen M. · Hallikainen M. · Mannermaa A. · Soininen H.
aDepartment of Neuroscience and Neurology, Brain Research Unit, Clinical Research Centre, Mediteknia, University of Kuopio; bDepartment of Neurology, Kuopio University Hospital and cDepartment of Pathology, University of Kuopio, Kuopio, Finland and dAging Research Center, Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Stockholm, Sweden

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Mild cognitive impairment (MCI) has attracted considerable interest as a potential predictor of Alzheimer’s disease (AD). Both the apolipoprotein E (ApoE) ε4 allele and vascular factors have been associated with a higher risk for AD, recently they have also been linked to the risk of MCI. Objectives: To estimate the incidence of MCI among cognitively healthy elderly subjects during a 3-year follow-up, and to evaluate the impact of demographic and vascular factors as well as the ApoE ε4 allele on the conversion to MCI. Methods: At baseline, the cognitive abilities of 806 out of 1,150 eligible subjects (aged 60–76 years) from a population-based sample were examined. Cognitively intact subjects (n = 747) were followed for an average of 3 years. Results: 66 subjects (8.8%) had converted to MCI. The global incidence rate of MCI was 25.94/1,000 person-years. Persons with higher age (OR 1.08, 95% CI 1.01–1.16), ApoE ε4 allele carriers (OR 2.04, 95% CI 1.15–3.64) and persons with medicated hypertension (OR 1.86, 95% CI 1.05–3.29) were more likely to convert to MCI than those individuals of lower age and without an ApoE ε4 allele or medicated hypertension. Persons with high education (OR 0.79, 95% CI 0.70–0.89) were less likely to convert to MCI than persons with low or no education. In subjects with both the ApoE ε4 allele and medicated hypertension, the crude OR for conversion was 3.92 (95% CI 1.81–8.49). In subjects with cardiovascular disease, the crude OR for conversion was 2.13 (95% CI 1.26–3.60). Gender, elevated blood pressure, diabetes or cerebrovascular disease had no significant effect on the conversion to MCI. Conclusion: Higher age, the presence of at least one ApoE ε4 allele and medicated hypertension are independent risk factors, but high education is a protective factor for MCI. The results suggest that vascular factors may have an important role in the pathogenesis of MCI.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Flicker C, Ferris SH, Reisberg B: Mild cognitive impairment in the elderly: Predictors of dementia. Neurology 1991;41:1006–1009.
  2. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG: Aging, memory, and mild cognitive impairment. Int Psychogeriatr 1997;9(suppl 1):65–69.
  3. Frisoni GB, Fratiglioni L, Fastbom J, Guo Z, Viitanen M, Winblad B: Mild cognitive impairment in the population and physical health: Data on 1,435 individuals aged 75–95. J Gerontol 2000;55A:322–328.
  4. Kivipelto M, Helkala EL, Hänninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and late-life mild cognitive impairment. A population-based study. Neurology 2001;56:1683–1689.
  5. DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Carmelli D: Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung and Blood Institute Twin Study. Arch Neurol 2001;58:643–647.
  6. Hänninen T, Hallikainen M, Tuomainen S, Vanhanen M, Soininen H: Prevalence of mild cognitive impairment: A population-based study in elderly subjects. Acta Neurol Scand 2002;106:148–154.
  7. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J: Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198–205.
  8. Larrieu S, Letenneuer L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, Barberger-Gateau P, Dartigues JF: Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002;59:1594–1599.
  9. Palmer K, Wang HX, Bäckman L, Winblad B, Fratiglioni L: Differential evolution of cognitive impairment in nondemented older persons: Results from the Kungsholmen Project. Am J Psychiatry 2002;159:436–442.
  10. Ritchie K, Artero S, Touchon J: Classification criteria for mild cognitive impairment. A population-based validation study. Neurology 2001;56:37–42.
  11. Jelle Visser P, Verhey FR, Jolles J, Jonker C: Course of minimal dementia and predictors of outcome. Int J Geriatr Psychiatry 2002;17:835–841.
  12. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–1992.
  13. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, De Kosky ST: Practice parameter – Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133–1142.
  14. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  15. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L: Mild cognitive impairment represents early-stage Alzheimer’s disease. Arch Neurol 2001;58:397–405.
  16. Lautenschlager NT, Riemenschneider M, Drzezga A, Kurz AF: Primary degenerative mild cognitive impairment: Study population, clinical, brain imaging and biochemical findings. Dement Geriatr Cogn Disord 2001;12:379–386.
  17. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A: 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141–1145.
  18. Launer LJ, Ross GB, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ: Midlife blood pressure and dementia: The Honolulu-Asia aging study. Neurobiol Aging 2000;21:49–55.
  19. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and Alzheimer’s disease in later life: Longitudinal, population-based study. BMJ 2001;322:1447–1451.
  20. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A: Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer’s disease. Neuroepidemiology 1998;17:14–20.
  21. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ: The association between midlife blood pressure levels and late-life cognitive functions. The Honolulu-Asia aging study. JAMA 1995;274:1846–1851.
  22. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H: Hypertension is related to cognitive impairment. A 20-year follow-up of 999 men. Hypertension 1998;31:780–786.
  23. Carmelli D, Swan GE, Reed T, Miller B, Wolf PA, Jarvik GP, Schellenberg GP: Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology 1998;50:1580–1585.
  24. Elias MF, Wolf PA, D’Agostino RB, Cobb J, White LR: Untreated blood pressure level is inversely related to cognitive functioning: The Framingham study. Am J Epidemiol 1993;138:353–364.
  25. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, McGovern P, Folsom AR: Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001;56:42–48.
  26. Goldstein IB, Bartzokis G, Guthrie D, Shapiro D: Ambulatory blood pressure and brain atrophy in the healthy elderly. Neurology 2002;59:713–719.
  27. Menzel HJ, Kladezky RG, Assmann G: Apolipoprotein E polymorphism and coronary heart disease. Arteriosclerosis 1983;3:310–315.
  28. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Perioak-Vance MA, Risch N, van Duijn CM: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer’s disease: A meta-analysis. JAMA 1997;278:1349–1356.
  29. Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, van Harskamp F, van Duijn CN, van Broeckhoven C, Grobbee DE: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam study. Lancet 1997;349:151–154.
  30. Prince M, Lovestone S, Cervilla J, Joels S, Powell J, Russ C, Mann A: The association between ApoE and dementia does not seem to be mediated by vascular factors. Neurology 2000;54:397–402.
  31. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H: Apolipoprotein E ε4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer’s disease. Ann Intern Med 2002;137:149–155.
  32. Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Covhran EJ, Berry-Kravis E, Bach J, Fox JH, Evans DA, Bennett DA: The apolipoprotein E ε4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol 2002;59:1154–1160.
  33. Den Heijer T, Oudkerk M, Launer LJ, van Duijn CM, Hofman A, Breteler MMB: Hippocampal, amygdalar and global brain atrophy in different apolipoprotein E genotypes. Neurology 2002;59:746–748.
  34. Lehtovirta M, Laakso MP, Soininen H, Helisalmi S, Mannermaa A, Helkala EL, Partanen K, Ryynänen M, Vainio P, Hartikainen P, Riekkinen PJ Sr: Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 1995;67:65–72.

    External Resources

  35. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, APA, 1994.
  36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–944.
  37. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, Kokmen E, Waring SC, Kurland LT: Apolipoprotein E status as a predictor of development of Alzheimer’s disease in memory-impaired individuals. JAMA 1995;273:1274–1278.
  38. Morris JC: The Clinical Dementia Rating: Current version and scoring rules. Neurology 1993;43:2412–2414.
  39. Russel EW: A multiple scoring method for the assessment of complex memory functions. J Cons Clin Psychol 1975;43:800–809.

    External Resources

  40. Wechsler D: Wechsler Memory Scale – Revised Manual. San Antonio, Psychological Corporation, 1987.
  41. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C, the CERAD investigators: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989;39:1159–1165.
  42. Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B: Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol 1999;12:168–179.
  43. Kaplan EF, Goodglass H, Weintraub S: The Boston Naming Test. Boston, Kaplan & Goodglass, 1991.
  44. Wechsler D: Wechsler Adult Intelligence Scale – Revised. Cleveland, Psychological Corporation, 1981.
  45. Borkowski JG, Benton AL, Spreen O: Word fluency and brain damage. Neuropsychologia 1967;5:135–140.

    External Resources

  46. Butters N, Granholm E, Salmon DP, Grant I: Episodic and semantic memory: A comparison of amnesic and demented patients. J Clin Exp Neuropsychol 1987;9:479–497.
  47. Reitan RM: Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271–276.
  48. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189–198.
  49. Meyer JS, Rauch G, Rauch RA, Haque A: Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol Aging 2000;21:161–169.
  50. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R: The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002;58:1175–1181.
  51. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA: Association of incident Alzheimer’s disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 2001;58:1640–1646.
  52. Farkas E, Luiten PG: Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog Neurobiol 2001;64:575–611.
  53. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215–1222.
  54. DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Garner J, Jack L, Carmelli D: Predictors of brain morphology for the men of the NHLBI twin study. Stroke 1999;30:529–536.
  55. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ: Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS. Neurobiol Aging 2000;21:57–62.
  56. Sparks DL, Scheff S, Liu H, Landers TM, Coyne CM, Hunsaker JC: Increased incidence of neurofibrillary tangles in non-demented individuals with hypertension. J Neurol Sci 1995;131:162–169.

    External Resources

  57. Zuccalà G, Onder G, Pedone C, Carosella L, Pahor M, Bernabei R, Cocchi A: Hypotension and cognitive impairment. Selective association in patients with heart failure. Neurology 2001;57:1986–1992.
  58. Cedazo-Minguez A, Cowburn RF: Apolipoprotein E: A major piece in the Alzheimer’s disease puzzle. J Cell Mol Med 2001;3:254–266.
  59. Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, Cochran EJ, Berry-Kravis E, Bienias JL: Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer’s disease. Neurology 2003;60:246–252.
  60. Launer LJ, Andersen K, Dewey ME, Letenneuer L, Ott A, Amaducci LA, Brayne C, Copeland JRM, Dartigues JF, Kragh-Sorensen P, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A: Rates and risk factors for dementia and Alzheimer’s disease. Results from EURODEM pooled analyses. Neurology 1999;52:78–84.
  61. Stern Y, Albert S, Tang MX, Tsai WY: Rate of memory decline in AD is related to education and occupation. Cognitive reserve? Neurology 1999;53:1942–1947.
  62. Launer LJ, Wind AW, Deeg DJ: Nonresponse pattern and bias in a community-based cross-sectional study of cognitive functioning among the elderly. Am J Epidemiol. 1994;139:803–812.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50